Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Target Price
The average target price of MNMD is 29 and suggests 67% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell